Anti-MDA5 dermatomyositis after COVID-19 vaccination: a case-based review

Area of Science:

• Immunology
• Rheumatology
• Infectious Diseases

Background:

• Anti-melanoma differentiation-associated protein 5 (MDA5) myositis is a rare dermatomyositis subtype.
• It presents with severe skin lesions and a high risk of interstitial lung disease.
• MDA5 is a sensor for viral RNA, including SARS-CoV-2, and can be activated by mRNA vaccines.

Purpose of the Study:

• To investigate the association between COVID-19 vaccines and the development of anti-MDA5 dermatomyositis.
• To report new cases of anti-MDA5 myositis following COVID-19 vaccination.
• To review existing literature on vaccine-associated myositis.

Main Methods:

• Literature review of anti-MDA5 myositis and COVID-19 vaccine.
• Case series of six patients who developed anti-MDA5 myositis post-vaccination.
• Analysis of clinical presentation and outcomes.

Main Results:

• Six new cases of anti-MDA5 myositis were identified shortly after COVID-19 vaccination.
• One prior case of vaccine-associated anti-MDA5 myositis was found in the literature.
• The findings suggest a potential link between COVID-19 vaccination and anti-MDA5 myositis.

Conclusions:

• COVID-19 vaccination may trigger anti-MDA5 myositis in susceptible individuals.
• Further research is needed to understand the mechanisms and incidence of this association.
• Vaccination remains crucial, and these findings should not deter public health efforts.